The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.
 
Ying Cheng
No Relationships to Disclose
 
Liang Han
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Jun Chen
No Relationships to Disclose
 
Hongmei Sun
No Relationships to Disclose
 
Guilan Wen
No Relationships to Disclose
 
Yinghua Ji
Research Funding - AoSaiKang (Inst); CSPC Pharmaceutical Group (Inst); Hualan Bio (Inst)
 
Anastasia V. Zimina
No Relationships to Disclose
 
Jianhua Shi
No Relationships to Disclose
 
Zhijie Pan
No Relationships to Disclose
 
Jinsheng Shi
No Relationships to Disclose
 
Xicheng Wang
No Relationships to Disclose
 
Yuansong Bai
No Relationships to Disclose
 
Tamar Melkadze
No Relationships to Disclose
 
Yueyin Pan
No Relationships to Disclose
 
Xuhong Min
No Relationships to Disclose
 
Maksym Viguro
No Relationships to Disclose
 
Jing Li
Employment - Shanghai Henlius Biotech
 
Qingyu Wang
Employment - Shanghai Henlius Biotech
 
Jun Zhu
Employment - Shanghai Henlius Biotech